Logo-npj
Submitted: 07 May 2020
Accepted: 24 Jun 2020
ePublished: 17 Jul 2020
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Nephropharmacol. 2021;10(1): e05.
doi: 10.34172/npj.2021.05
  Abstract View: 409
  PDF Download: 218

Mini-Review

An overview of complications associated with deferoxamine therapy in thalassemia

Bijan Keikhaei 1 ORCID logo, Neda Farmani-Anooshe 1, Mohammad Bahadoram 1 * ORCID logo, Mohammad-Reza Mahmoudian-Sani 1, Kosar Alikhani 1 ORCID logo, Ammar Helalinasab 1 ORCID logo

1 Thalassemia and Hemoglobinopathy Research Center, Research Institute of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
*Corresponding author: Mohammad Bahadoram, Email: mohammadbahadoram@yahoo.com, Bahadoram.m@ajums.ac.ir

Abstract

Thalassemic syndromes are the most common genetic diseases in the world that are related to blood transfusion and iron overload in the body. In ß-thalassemia major multiple blood transfusions due to ineffective erythropoiesis lead to iron excess in the body. Iron chelating agent deferoxamine is used to treat chronic iron overload in patients with β-thalassemia in an attempt to reduce morbidity and mortality related to deposition of excess iron in body tissue. However, a very short half-time, the need of repetitive injections and non-specialized distribution in tissues can lead to side effects, such as ophthalmic and renal complications, neurological, skeletal changes and hearing loss, headaches, and infection too. Patients should be monitored periodically for complications. The risk of toxic effects in doses of more than 50 mg/kg/d is higher. Keeping deferoxamine therapeutic index can avoid drug overdose and side effects.
Keywords: Deferoxamine, Thalassemia, Chelators

Implication for health policy/practice/research/medical education:Deferoxamine is used to treat chronic iron overload in patients with β-thalassemia. Short half-time of deferoxamine and the need of repetitive injections can lead to side effects. Patients should be monitored periodically for complications. Keeping deferoxamine therapeutic index can avoid drug overdose and side effects.

Please cite this paper as: Keikhaei B, Farmani-Anooshe N, Bahadoram M, Mahmoudian-Sani MR, Alikhani K, Helalinasab A. An overview of complications associated with deferoxamine therapy in thalassemia. J Nephropharmacol. 2021;10(1):e05. DOI: 10.34172/npj.2021.05.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 409

Your browser does not support the canvas element.


PDF Download: 218

Your browser does not support the canvas element.